Home › Funds › 683 Capital Management, LLC › LXEO

683 Capital Management, LLC position in LXEO

LEXEO THERAPEUTICS INC COM · Health Care

683 Capital Management, LLC reported holding 1,875,000 shares of LXEO (LEXEO THERAPEUTICS INC COM) in its Q2 2026 13F filing — a position valued at US$8.7M, representing 0.46% of its reported portfolio and ranking #49 among its reported holdings. 683 Capital Management, LLC has disclosed LXEO holdings in 4 of the last 4 reported quarters, going back to Q3 2025.

Latest position (Q2 2026)1.88M sh
Reported value held$8.73M
Portfolio Weight0.46%
First reportedQ3 2025
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How 683 Capital Management, LLC's LXEO position evolved

683 Capital Management, LLC first disclosed a stake in LXEO in Q3 2025 at 922,662 shares (US$6.1M). The position peaked in Q4 2025 at 1,120,000 shares, worth US$11.1M. Across 4 filings, 683 Capital Management, LLC increased the stake 3 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 1,875,000 shares valued at US$8.7M — an increase of 675,000 shares quarter over quarter.. Notable position changes include a 56% increase in Q2 2026 (shares fell 27% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2025 922.66K $6.13M New
Q4 2025 1.12M $11.12M Add
Q1 2026 1.20M $6.89M Add
Q2 2026 1.88M $8.73M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About LXEO and 13F data

LXEO (LEXEO THERAPEUTICS INC COM) is a Health Care company. 40 other funds we track also report a position in LXEO — the largest reported positions include MONTANOVA CAPITAL, LLC (US$29.7M), Affinity Asset Advisors, LLC (US$27.0M), Frazier Life Sciences Management, L.P. (US$22.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding LXEO

All LXEO fund holders →

FAQ

How long has 683 Capital Management, LLC held LXEO?

683 Capital Management, LLC has disclosed LXEO holdings in 4 of the last 4 reported quarters, going back to Q3 2025.

What is 683 Capital Management, LLC's current position in LXEO?

As of Q2 2026, 683 Capital Management, LLC holds 1.88M shares of LXEO (LEXEO THERAPEUTICS INC COM), valued at $8.73M, representing 0.46% of its reported portfolio and ranking #49.

Has 683 Capital Management, LLC been buying or selling LXEO?

In the latest 13F filing (Q2 2026), 683 Capital Management, LLC increased its position in LXEO. The position peaked in Q4 2025 at 1.12M shares.

Which other funds hold LXEO?

Other major institutional holders of LXEO include MONTANOVA CAPITAL, LLC, Affinity Asset Advisors, LLC, Frazier Life Sciences Management, L.P., among 40 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.